Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the... Biopharmaceuticals, Oncology, FDA Progenics Pharmaceuticals, AZEDRA, iobenguane, Pheochromocytoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Marketing | New Drug Applications | Paraganglioma | Pharmaceuticals | Pheochromocytoma